Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity

Life Sciences

Volumn 71, Issue 13, 2002, Pages 1579-1589

  Zou, L ^a   Harkey, M R ^a   Henderson, G L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytochrome P450; Drug herb interactions; Herbal components; Marker compounds

Indexed keywords

ALLICIN; BILOBALIDE; CATECHIN; COMPLEMENTARY DNA; CYTOCHROME P450; DESMETHOXYYANGONIN; DIHYDROKAWAIN; DIHYDROMETHYSTICIN; ESCIN; FURAFYLLINE; GINKGO BILOBA EXTRACT; GINKGOLIC ACID; GINKGOLIDE A; GINKGOLIDE B; GINKGOLIDE C; HERBACEOUS AGENT; HYPERFORIN; ISOENZYME; ISORHAMNETIN; KAVA; KETOCONAZOLE; LINOLEIC ACID; METHYSTICIN; NARINGENIN; PRIMROSE OIL; QUERCETIN; QUINIDINE; SULFAPHENAZOLE; TRANYLCYPROMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CATALYSIS; DRUG EFFECT; DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; GARLIC; GINKGO BILOBA; HYPERICUM PERFORATUM; IC 50;

BIOLOGICAL MARKERS; CATALYSIS; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; ENZYME INHIBITORS; HUMANS; ISOENZYMES; PLANT EXTRACTS; RECOMBINANT PROTEINS;

ALLIUM SATIVUM; GINKGO BILOBA; OENOTHERA; PIPER METHYSTICUM; PRIMULA;

EID: 0037119057     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(02)01913-6     Document Type: Article

References (50)

1. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450
2. Effects of ginseng components on cDNA-expressed cytochrome P450 enzyme catalytic activity
3. An in vitro evaluation of human cytochrome P450 3A4 inhbition by selected commercial herbal extracts and tinctures
4. Variability in commercial ginseng products: An analysis of 25 preparations
5. Effects of intrinsic fluorescence and quenching on fluorescence-based screening of natural products
6. Herb sales down 15 percent in mainstream market
7. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
8. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry
9. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression [see comments]
10. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins
11. Grapefruit juice and drugs. How significant is the interaction?
12. Grapefruit juice increases oral nimodipine bioavailability
13. The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice
14. Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy
15. Influence of grapefruit juice on cisapride pharmacokinetics
16. Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers
17. Effect of grapefruit juice on blood cyclosporin concentration
18. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice
19. Interaction between grapefruit juice and midazolam in humans
20. Dramatic inhibition of amiodarone metabolism induced by grapefruit juice
21. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin
22. Grapefruit juice inhibits 7-hydroxylation of coumarin in healthy volunteers
23. Grapefruit juice can increase the plasma concentrations of oral methylprednisolone
24. Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics
25. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression
26. St John's Wort: Effect on CYP3A4 activity
27. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4
28. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor
29. Indinavir concentrations and St. John's wort
30. Acute heart transplant rejection due to Saint John's wort
31. Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation
32. Drug interaction of St John's wort with cyclosporin
33. Drug interaction between St. John's wort and cyclosporine
34. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)
35. St John's wort interaction with digoxin
36. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers
37. Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers
38. Garlic supplements decrease saquinavir plasma concentrations
39. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion
40. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract
41. Gingko biloba: A case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy
42. Association of Ginkgo biloba with intracerebral hemorrhage
43. Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man
44. Coma in a patient with Alzheimer's disease taking low dose trazodone and gingko biloba [letter]
45. Coma from the health food store: Interaction between kava and alprazolam
46. Positive interaction of ethanol and kava resin in mice
47. Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19
48. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism
49. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
50. Extensive binding of the bioflavonoid quercetin to human plasma proteins